Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,24
KB-0,22
PKN97,6497,90,66
Msft0,61
Nokia4,724,7491,00
IBM0,13
Daimler AG57,7257,760,70
PFE0,71
22.9.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.9.2018
Adamis Pharma (NASDAQ Cons)
Závěr k 21.9.2018 Změna (%) Změna (USD) Objem obchodů (ks)
3,10 1,64 0,05 1 948 265
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.9.2018
Popis společnosti
Obecné informace
Název společnostiAdamis Pharmaceuticals Corp
TickerADMP
Kmenové akcie:Ordinary Shares
RICADMP.O
ISINUS00547W2089
Prioritní akcieConv. Pref. Shrs Series A
Prioritní akciePreference Shares Series A2
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 31.12.2017 108
Akcie v oběhu k 7.8.2018 47 291 358
Počet akcionářů k 31.12.2017 91
MěnaUSD
Kontaktní informace
Ulice11682 El Camino Real Ste 300
MěstoSAN DIEGO
PSČ92130-2092
ZeměUnited States
Kontatní osobaMark Gundy
Funkce kontaktní osobyIR Contact Officer
Telefon18 589 972 400
Fax13026365454
Kontatní telefon19 722 401 873

Business Summary: Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Financial Summary: BRIEF: For the six months ended 30 June 2018, Adamis Pharmaceuticals Corp revenues increased 4% to $7.1M. Net loss increased 61% to $17.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.7M to $7.1M (expense), Selling general & administrative expense increase of 14% to $12.8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSInVitro Diagnostic Substance Manufacturing
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDiagnostic Substances



  • Poslední aktualizace: 22.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardRichard Williams7225.8.2014
President, Chief Executive Officer, DirectorDennis Carlo711.4.20091.4.2009
Chief Financial Officer, Vice President - FinanceRobert Hopkins541.4.20091.4.2009
Senior Vice President - Corporate Development, DirectorDavid Marguglio441.4.2009
Vice President - OperationsKaren Daniels62
Vice President - Commercial OperationsGus Fernandez5415.4.201515.4.2015
Vice President - ResearchThomas Moll49